Literature DB >> 26525963

Pre-hypertension: Is it an inflammatory state?

H Nandeesha1, Zachariah Bobby2, N Selvaraj3, Medha Rajappa2.   

Abstract

Even though several studies have implicated the role of inflammation in the pathogenesis of hypertension and other cardiovascular disease, there are only limited studies about inflammatory markers in prehypertension. The objective of the present article was to review the role of markers like C-reactive protein, interleukin-6, tumor necrosis factor-α and sialic acid in prehypertension. An extensive literature search was made in Pubmed (http://www.ncbi.nlm.nih.gov/pubmed/) using phrases such as prehypertension, inflammation, C-reactive protein, cardiovascular disease, cytokines and sialic acid. Several investigators have reported increased inflammatory markers like C-reactive protein, interleukin-6, tumor necrosis factor-α and sialic acid in prehypertension indicating the role of inflammation in the pathogenesis of prehypertension and its complications. Elevated inflammatory markers may enhance the risk for cardiovascular disease in subjects with prehypertension.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  C-reactive protein; Cardiovascular disease; Interleukin-6; Prehypertension; Sialic acid; Tumor necrosis factor-α

Mesh:

Substances:

Year:  2015        PMID: 26525963     DOI: 10.1016/j.cca.2015.10.022

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  8 in total

1.  Double positivity of the IgG isotype of both anticardiolipin and anti-β2gpI antibodies is associated with the highest number of vascular impairment parameters in patients with primary antiphospholipid syndrome: preliminary data.

Authors:  Mirjana Bećarević; Duško Mirković; Svetlana Ignjatović
Journal:  Clin Rheumatol       Date:  2016-10-14       Impact factor: 2.980

2.  Inflammation and Apparent Treatment-Resistant Hypertension in Patients With Chronic Kidney Disease.

Authors:  Jing Chen; Joshua D Bundy; L Lee Hamm; Chi-Yuan Hsu; James Lash; Edgar R Miller; George Thomas; Debbie L Cohen; Matthew R Weir; Dominic S Raj; Hsiang-Yu Chen; Dawei Xie; Panduranga Rao; Jackson T Wright; Mahboob Rahman; Jiang He
Journal:  Hypertension       Date:  2019-04       Impact factor: 10.190

Review 3.  Polyphenols: a Promising Nutritional Approach to Prevent or Reduce the Progression of Prehypertension.

Authors:  Sergio Davinelli; Giovanni Scapagnini
Journal:  High Blood Press Cardiovasc Prev       Date:  2016-04-26

4.  Associations of urinary sodium and sodium to potassium ratio with hypertension prevalence and the risk of cardiovascular events in patients with prehypertension.

Authors:  Xin Zhao; Yan Zhang; Xiaolin Zhang; Yi Kang; Xiaoxiang Tian; Xiaozeng Wang; Junyin Peng; Zhiming Zhu; Yaling Han
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-10-31       Impact factor: 3.738

5.  The effect of dexmedetomidine on the perioperative hemodynamics and postoperative cognitive function of elderly patients with hypertension: Study protocol for a randomized controlled trial.

Authors:  Xuejiang Du; Jianshe Yu; Weidong Mi
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

6.  Sympathoexcitation and impaired arterial baroreflex sensitivity are linked to vascular inflammation in individuals with elevated resting blood pressure.

Authors:  Ida T Fonkoue; Ngoc-Anh Le; Melanie L Kankam; Dana DaCosta; Toure N Jones; Paul J Marvar; Jeanie Park
Journal:  Physiol Rep       Date:  2019-04

7.  Is Office Blood Pressure Measurement Reliable in Obese Adolescents?

Authors:  Derya Tepe; Songül Yılmaz
Journal:  Diabetes Metab Syndr Obes       Date:  2021-09-01       Impact factor: 3.168

8.  Negative association between lipoprotein associated phospholipase A2 activity and baroreflex sensitivity in subjects with high normal blood pressure and a positive family history of hypertension.

Authors:  D Čelovská; K Vlčková; J Gonsorčík
Journal:  Physiol Res       Date:  2021-03-08       Impact factor: 1.881

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.